Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - ceftazidime pentahydrate 291.2mg equivalent to 250 mg ceftazidime - powder for injection - 250 mg - active: ceftazidime pentahydrate 291.2mg equivalent to 250 mg ceftazidime excipient: nitrogen sodium carbonate - ceftazidime sandoz is indicated for the treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. indications include: severe infections e.g. septicaemia, bacteraemia, peritonitis, meningitis; infections in immunosuppressed patients; infections in patients in intensive care, e.g. infected burns; respiratory tract infections including lung infections in cystic fibrosis; ear, nose and throat infections; urinary tract infections; skin and soft tissue infections; gastrointestinal, biliary and abdominal infections; bone and joint infections; infections associated with haemo-and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - ceftazidime pentahydrate 2329.6mg equivalent to 2 g ceftazidime - powder for injection - 2 g - active: ceftazidime pentahydrate 2329.6mg equivalent to 2 g ceftazidime excipient: nitrogen sodium carbonate - ceftazidime sandoz is indicated for the treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. indications include: severe infections e.g. septicaemia, bacteraemia, peritonitis, meningitis; infections in immunosuppressed patients; infections in patients in intensive care, e.g. infected burns; respiratory tract infections including lung infections in cystic fibrosis; ear, nose and throat infections; urinary tract infections; skin and soft tissue infections; gastrointestinal, biliary and abdominal infections; bone and joint infections; infections associated with haemo-and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - ceftazidime pentahydrate 582.4mg equivalent to 500 mg ceftazidime - powder for injection - 500 mg - active: ceftazidime pentahydrate 582.4mg equivalent to 500 mg ceftazidime excipient: nitrogen sodium carbonate - ceftazidime sandoz is indicated for the treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. indications include: severe infections e.g. septicaemia, bacteraemia, peritonitis, meningitis; infections in immunosuppressed patients; infections in patients in intensive care, e.g. infected burns; respiratory tract infections including lung infections in cystic fibrosis; ear, nose and throat infections; urinary tract infections; skin and soft tissue infections; gastrointestinal, biliary and abdominal infections; bone and joint infections; infections associated with haemo-and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - ceftazidime - powder for solution for injection/infusion - 1 gram(s) - third-generation cephalosporins; ceftazidime

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - ceftazidime - powder for solution for injection/infusion - 2 gram(s) - third-generation cephalosporins; ceftazidime

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - ceftriaxone - powder for solution for injection/infusion - 1 gram(s) - third-generation cephalosporins; ceftriaxone

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - ceftriaxone sodium - powder for solution for injection/infusion - 2 gram(s) - third-generation cephalosporins; ceftriaxone

Marekani - Kiingereza - NLM (National Library of Medicine)

sandoz inc - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime anhydrous 1 g - ceftazidime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: ceftazidime for injection, usp may be used alone in cases of confirmed or suspected sepsis. ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibiotics have been used. ceftazidime for injection, usp may also be used concomitantly with other antibiotics, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. when such concomitant treatment is appropriate, prescribing information in the labeling for the other antibiotics should be followed. the dose depends on the severity of the infection and the patient’s condition. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection, usp and other antibacterial drugs, ceftazidime f

Marekani - Kiingereza - NLM (National Library of Medicine)

sagent pharmaceuticals - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime anhydrous 6 g in 30 ml - ceftazidime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections , including pneumonia, caused by pseudomonas aeruginosa and other pseudomonas spp.; haemophilus influenzae , including ampicillin-resistant strains; klebsiella spp.; enterobacter spp.; proteus mirabilis; escherichia coli; serratia spp.; citrobacter spp.; streptococcus pneumoniae; and staphylococcus aureus (methicillin-susceptible strains). - skin and skin-structure infections caused by pseudomonas aeruginosa; klebsiella spp.; escherichia coli; proteus spp., including proteus mirabilis and indole-positive proteus; enterobacter spp.; serratia spp.; staphylococcus aureus (methicillin-susceptible strains); and streptococcus pyogenes (group a beta-hemolytic streptococci). - urinary tract infections , both complicated and uncomplicated, caused by pseudomonas aeruginosa; enterobacter s

Marekani - Kiingereza - NLM (National Library of Medicine)

wg critical care, llc - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime anhydrous 6 g in 100 ml - ceftazidime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. lower respiratory tract infections, including pneumonia, caused by pseudomonas aeruginosa and other pseudomonas spp.; haemophilus influenzae, including ampicillin-resistant strains; klebsiella spp.; enterobacter spp.; proteus mirabilis; escherichia coli; serratia spp.; citrobacter spp.; streptococcus pneumoniae; and staphylococcus aureus (methicillin-susceptible strains). 2. skin and skin-structure infections caused by pseudomonas aeruginosa; klebsiella spp.; escherichia coli; proteus spp., including proteus mirabilis and indole-positive proteus; enterobacter spp.; serratia spp.; staphylococcus aureus (methicillin-susceptible strains); and streptococcus pyogenes (group a beta-hemolytic streptococci). 3. urinary tract infections, both complicated and uncomplicated, caused by pseudomonas aeruginosa; enterobacter spp.